Identification of a serotonin/glutamate receptor complex implicated in psychosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception. Some antipsychotic drugs were identified by their high affinity for serotonin 5-HT2A receptors (2AR). Drugs that interact with metabotropic glutamate receptors (mGluR) also have potential for the treatment of schizophrenia. The effects of hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble some of the core symptoms of schizophrenia. Here we show that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex. The 2AR-mGluR2 complex triggers unique cellular responses when targeted by hallucinogenic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural responses. In post-mortem human brain from untreated schizophrenic subjects, the 2AR is upregulated and the mGluR2 is downregulated, a pattern that could predispose to psychosis. These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Temporal pattern encoding relieves the cellular information bottleneck, where many stimuli must signal through few intracellular pathways to generate diverse and specific cellular responses (30 -32) but complicates the relationship between synthetic target modulators and their cellular and clinical effects.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several recent studies of drugs acting at cell surface receptor targets show that the activation mechanisms responsible for their cellular and systemic effects are more complex than accounted for by their classical pharmacological profiles (30 -32).”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled Receptor
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H.-J., Kuhn, P., Weis, W. I., Kobilka, B. K., et al. (2007) · Science · doi:10.1126/science.1150577 · Cited by 3,264
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Self-citation
Cited by
Items 201–300 of 835
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., Kornhuber, J., Quednow, B. B., & Müller, C. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00152 · Cited by 76
“A decade ago, it has been proposed that only 5-HT2A-Rs coupled to metabotropic mGluR2 mediate the psychotogenic effects of 5-HT hallucinogens (196)—a position that has been questioned recently (197).”
BackgroundGPCR heteromers: An overview of their classification, function and physiological relevance
Dale, N. C., Johnstone, E. K. M., & Pfleger, K. D. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.931573 · Cited by 70
“It has been demonstrated that 5-HT2A and mGluR2 form a heteromer in native tissue (131) and that in a non-pathological state this heteromer acts to modulate signal transduction through each receptor protomer to increase Gai signalling and decrease Gaq signalling (130).”
BackgroundAira, Z., Buesa, I., Salgueiro, M., Bilbao, J., Aguilera, L., Zimmermann, M., & Azkue, J. J. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.032 · Cited by 72
Marek, G. J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_480 · Cited by 75
Gregory, K. J., & Goudet, C. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.019133 · Cited by 69
New therapeutic opportunities for 5-HT2 receptor ligands
Maroteaux, L., Ayme‐Dietrich, E., Aubertin-Kirch, G., Banas, S. M., Quentin, E., Lawson, R., & Monassier, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.008 · Cited by 66
King, D. B., Mara, C. A., & DeCicco, T. L. (2012) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2012.31.1.11 · Cited by 66
Triplet Puzzle: Homologies of Receptor Heteromers
Tarakanov, A. O., & Fuxé, K. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9313-5 · Cited by 65
CrossTalk proposal: Weighing the evidence for Class A GPCR dimers, the evidence favours dimers
Bouvier, M., & Hébert, T. E. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272252 · Cited by 72
“Studies using binding-impaired mutant D2 dopamine and 5-HT4 receptors have also demonstrated asymmetries between GPCR dimers and G protein coupling (Han et al. 2009; Pellissier et al. 2011).”
BackgroundGroup II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs
Muguruza, C., Meana, J. J., & Callado, L. F. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00130 · Cited by 72
“This serotonin-glutamate heterocomplex has been involved in the mechanism of action of both hallucinogenic (Gonzalez-Maeso et al., 2003, 2007; Moreno et al., 2011a) and antipsychotic drugs (Fribourg et al., 2011).”
BackgroundSelf-citationFully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo
de la Fuente Revenga, M., Shin, J. M., Vohra, H. Z., Hideshima, K. S., Schneck, M., Poklis, J. L., & González-Maeso, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-49913-4 · Cited by 57
Self-citationBoczek, T., Mackiewicz, J., Sobolczyk, M., Wawrzyniak, J., Lisek, M., Ferenc, B., Guo, F., & Żylińska, L. (2021) · Cells · doi:10.3390/cells10051228 · Cited by 69
“On the other hand, postmortem study on untreated schizophrenic patients demonstrated up-regulation of 5HT2A receptor density in the PFC [160].”
BackgroundInfluentialShen, Y., & Niswender, C. M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.022 · Cited by 71
Neale, S. A., Copeland, C. S., Uebele, V. N., THOMSON, F. J., & Salt, T. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.4 · Cited by 64
“Altered activity of both VGLUT and Group II mGlu receptors has been linked to schizophrenia (Fell et al, 2011; Gonzalez-Maeso et al, 2008; Eastwood and Harrison, 2005; Varea et al, 2012).”
BackgroundStructure of metabotropic glutamate receptor C-terminal domains in contact with interacting proteins
Enz, R. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00052 · Cited by 68
“, and Sealfon, S. C. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis.”
BackgroundHoriguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2251-2 · Cited by 66
“mGlu2/3 and 5-HT2A receptors co-localize in cortical pyramidal neurons and form a heterodimer complex (González-Maeso et al. 2008).”
BackgroundG Protein–Coupled Receptor Multimers: A Question Still Open Despite the Use of Novel Approaches
Vischer, H. F., Castro, M., & Pin, J. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099440 · Cited by 69
Blasi, G., Selvaggi, P., Fazio, L., Antonucci, L. A., Taurisano, P., Masellis, R., Romano, R., Mancini, M., Zhang, F., Caforio, G., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.5 · Cited by 72
“Other investigations have revealed abnormal 5-HT2A expression and binding in patients with schizophrenia (Abi-Dargham, 2007; GonzalezMaeso et al, 2008) as well as a relationship between 5-HT2A binding and psychotic symptoms in antipsychotic-naive patients (Gonzalez-Maeso et al, 2008).”
BackgroundEpigenetic Mechanisms of Serotonin Signaling
Holloway, T., & González-Maeso, J. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00033 · Cited by 57
Self-citationGroup II metabotropic glutamate receptors and schizophrenia
Moreno, J. L., Sealfon, S. C., & González‐Maeso, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0130-3 · Cited by 67
“Recent findings showed that 5-HT2A and mGluR2 co-localize in cortical pyramidal neurons and form a receptor heterocomplex [53, 57].”
BackgroundResultInfluentialSelf-citationBrea, J. M., Castro, M., Giraldo, J., López‐Giménez, J. F., Padín, J. F., Quintián, F., Cadavid, M. I., Vilaró, M. T., Mengod, G., Berg, K. A., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.054395 · Cited by 62
Self-citationModulation of Chronic Pain by Metabotropic Glutamate Receptors
Chiechio, S. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2015.11.001 · Cited by 67
Li, X., Sun, Q., Zhao, H., Rovira, X., Gai, S., He, Q., Pin, J., Liu, J., & Rondard, P. (2019) · Nature Communications · doi:10.1038/s41467-019-10834-5 · Cited by 64
Aznar, S., & Klein, A. B. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8472-0 · Cited by 64
“psychosis as seen in schizophrenic patients [90].”
Trinquet, E., Bouhelal, R., & Dietz, M. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.608658 · Cited by 67
“Several studies have showed that GPCR complexes can modulate ligand-binding properties or trigger new cellular responses [81-83].”
BackgroundThe roles played by highly truncated splice variants of G protein-coupled receptors
Wise, H. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-13 · Cited by 61
“Evidence of heterodimerization of full length GPCRs in vivo has been harder to obtain, [67], but examples are available associated with pathophysiological conditions: angiotensin-II (AT1) – bradykinin receptor complexes in preeclampsia [68]; the μ-opioid receptor and α2A-adrenoceptor complex in depression and opioid a…”
BackgroundContribution of heteromerization to G protein-coupled receptor function
Gaitonde, S. A., & González‐Maeso, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.10.006 · Cited by 64
“Using wild-type 5-HT2C and wild-type mGlu3 receptors as well as mGlu2/mGlu3 chimeric constructs that form or do not form the 5-HT2A-mGlu2 heteromeric receptor complex, previous results suggest the existence of a crosstalk mechanism between these two receptors that requires their physical association [36 ,59,60,83].”
Self-citationThe Effects of Hallucinogens on Gene Expression
Martin, D. A., & Nichols, C. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_479 · Cited by 62
“Although there are reports of heterodimerization between these two receptors (Gonzalez-Maeso et al. 2008; Moreno et al. 2011), this conclusion has been controversial (Delille et al.”
BackgroundG protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)
Ferré, S., Ciruela, F., DESSAUER, C. W., González‐Maeso, J., Hébert, T. E., Jockers, R., Logothetis, D. E., & Pardo, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107977 · Cited by 61
“It is localized in cortical glutamatergic pyramidal neurons and represents an important target for the hallucinogenic effects of 5HT2AR agonists and the antipsychotic effect of both 5-HT2AR antagonists/inverse agonists and mGlu2R agonists (Baki et al., 2016; Fribourg et al., 2011; González-Maeso et al., 2008; Moreno e…”
BackgroundSelf-citationGroup II metabotropic glutamate receptor agonists as a potential drug for schizophrenia
Chaki, S. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.041 · Cited by 63
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 63
“In that sense, psilocybin would reduce relapse for alcohol through the interaction between 5-HT2A and mGluR2, which can assemble into a functional complex and modulate each other's function.(27,28) Interestingly, mGluR2 are particularly abundant in the neural circuits connecting the medial prefrontal cortex (mPFC) wit…”
BackgroundRoenker, N. L., Gudelsky, G. A., Ahlbrand, R., Bronson, S. L., Kern, J. R., Waterman, H., & Richtand, N. M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.011 · Cited by 73
“Functional interactions between serotonin 5-HT2A and glutamate mGluR2 receptors have been reported [10], providing a plausible mechanism linking 5HT2A receptor binding to modulation of extracellular glutamate.”
Backgrounddu Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
“…between the glutamatergic and the serotonergic system have been reported, which include a functional crosstalk between mGluR2 and 5-HT2A receptors (González-Maeso et al., 2008) (reviewed in Delille et al., 2013), NMDA and 5-HT1A receptors (Moraes et al., 2008; Yuen et al., 2005), and a functional…”
Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons
Battaglia, G., Molinaro, G., Riozzi, B., Storto, M., Busceti, C. L., Spinsanti, P., Bucci, D., Liberto, V. D., Mudò, G., Corti, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006591 · Cited by 62
“mGlu2/3 receptor agonists [33,35,36], while the mGlu3 receptor is still in search of a function that can be relevant for human”
BackgroundRole of Estrogen Treatment in the Management of Schizophrenia
Kulkarni, J., Gavrilidis, E., Worsley, R., & Hayes, E. (2012) · CNS Drugs · doi:10.2165/11630660-000000000-00000 · Cited by 64
“This is important given that, in addition to dopamine, other neurotransmitters such as serotonin and glutamate are likely involved in the pathophysiology of schizophrenia.([24]) Second-generation antipsychotic medications are effective both through the traditional antagonism of dopamine D2 receptors and through furthe…”
BackgroundLyon, L., Burnet, P. W. J., Kew, J. N. C., Corti, C., Rawlins, J. N. P., Lane, T. A., Filippis, B. D., Harrison, P. J., & Bannerman, D. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.145 · Cited by 60
“Finally, the expression and function of mGlu2 and mGlu3 may be altered in the disorder (eg, Gupta et al, 2005; Gonzalez-Maeso et al, 2008; Sartorius et al, 2008; Ghose et al, 2009).”
BackgroundŁukasiewicz, S., Błasiak, E., Szafran‐Pilch, K., & Dziedzicka‐Wasylewska, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13582 · Cited by 58
“Pharmaceutics targeting clinically relevant heteromers may have the potential to treat pain, asthma, Parkinson’s disease, schizophrenia, and diverse other disorders (McGraw et al. 2006; Carriba et al. 2007; Finley et al. 2008; Gonzalez-Maeso et al. 2008; Fuxe et al. 2009; Rivero-M€uller et al. 2013).”
BackgroundMelatonin Receptor Signaling: Impact of Receptor Oligomerization on Receptor Function
Oishi, A., Cecon, E., & Jockers, R. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.02.002 · Cited by 65
G Protein-Coupled Receptor Heteromers as New Targets for Drug Development
Ferré, S., Navarro, G., Casadó, V., Cortés, A., Mallol, J., Canela, E. I., Lluís, C., & Franco, R. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)91002-8 · Cited by 68
García‐Bea, A., Miranda-Azpiazu, P., Muguruza, C., Marmolejo-Martínez-Artesero, S., Díez-Alarcia, R., Gabilondo, A. M., Callado, L. F., Morentín, B., González‐Maeso, J., & Meana, J. J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.10.013 · Cited by 59
Self-citationMechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
“…of psychedelics on cellular, electrophysiological, and behavioral responses are blunted upon administration of the metabotropic glutamate receptor type 2/3 receptor (mGlu2/ 3) agonist LY379268 [75, 104], whereas psychedelic-induced HTR is augmented by the mGlu2/3 receptor antagonist LY341495 [105].”
Self-citationOn the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
Pałucha-Poniewiera, A., Wierońska, J. M., Brański, P., Stachowicz, K., Chaki, S., & Pilc, A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1978-5 · Cited by 57
“Functional and structural interaction between mGlu2 and 5HT2A receptors is well documented, and it is believed to be implicated in psychosis (González-Maeso et al. 2008; Kłodzińska et al. 2002; Marek et al. 2000).”
Copeland, C. S., Neale, S. A., & Salt, T. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.009 · Cited by 59
Blasi, G., Virgilio, C. D., Papazacharias, A., Taurisano, P., Gelao, B., Fazio, L., Ursini, G., Sinibaldi, L., Andriola, I., Masellis, R., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1378 · Cited by 61
Bruno, A., Guadix, A. E., & Costantino, G. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900067g · Cited by 58
Melatonin as a potential therapeutic agent in psychiatric illness
Maldonado, M. D., Reiter, R. J., & Pérez‐San‐Gregorio, M. A. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1032 · Cited by 54
“DOI: 10.1002/hup receptor upregulation and glutamate receptor desensitization are characteristics of altered cortical processes of schizophrenia (Gonzalez-Maeso et al., 2008).”
InfluentialPsychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects
Lester, H. A., Miwa, J. M., & Srinivasan, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.020 · Cited by 53
“Heterodimers between 5-HT2A and a metabotropic glutamate receptor, metabotropic glutamate receptor 2 (mGluR2), occur in cortical neurons (46,47).”
Iacovelli, L., Molinaro, G., Battaglia, G., Motolese, M., Menna, L. D., Alfiero, M., Blahoš, J., Matrisciano, F., Corsi, M., Corti, C., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052316 · Cited by 59
“In addition, mGlu2 receptors form functional complexes with 5-HT2A serotonergic receptors (González-Maeso et al., 2008) and mediate the ability of mGlu2/3 receptor agonists to inhibit cellular and behavioral responses to hallucinogenic drugs (Gewirtz and Marek, 2000; Marek et al.”
BackgroundInfluentialThe Role of Oestrogen and Other Hormones in the Pathophysiology and Treatment of Schizophrenia
Hayes, E., Gavrilidis, E., & Kulkarni, J. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/540273 · Cited by 61
“While the historical dopaminergic hyperactivity hypothesis of schizophrenia endures, it is now widely accepted that other major neurotransmitter systems such as serotonin and glutamate are also involved in the pathophysiology of the disorder [25, 26].”
BackgroundMurat, B., Devost, D., Andrés, M., Mion, J., Boulay, V., Corbani, M., Zingg, H. H., & Guillon, G. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1202 · Cited by 54
Hackler, E., Byun, N. E., Jones, C. K., Williams, J. M., Baheza, R., Sengupta, S., Grier, M. D., Avison, M. J., Conn, P. J., & Gore, J. C. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.057 · Cited by 58
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 57
Schwendt, M., Reichel, C. M., & See, R. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034299 · Cited by 59
“Disrupted mGluR2/3 and/or mGluR7 receptor function in the forebrain has also been implicated in deficits in cognitive processing often diagnosed in patients with schizophrenia [69], with findings from several preclinical models of schizophrenia as well as from postmortem studies showing decreased levels of mGluR2/3 re…”
BackgroundBrogaard, B. “. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00657 · Cited by 59
“When a hallucinogen binds to the 5-HT2A receptor, this gives rise to an excitatory response (Scruggs et al., 2003; Nichols, 2004).”
BackgroundInfluentialIasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140324183406 · Cited by 58
“On the other hand, it has been reported that activation of NMDA receptors favors recruitment of D1 receptors to the plasma membrane of cultured rat neostriatal neurons [154].”
BackgroundPałucha-Poniewiera, A., Kłodzińska, A., Stachowicz, K., Tokarski, K., Hess, G., Schann, S., Frauli, M., Neuville, P., & Pilc, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.033 · Cited by 56
Lysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 60
“The metabotropic glutamate receptor 2 which forms complexes with 5HT2A receptors is required for the pharmacological and behavioral effects [Gonzalez-Maeso et al. 2008; Moreno et al. 2011].”
Borroto-Escuela, D. O., Narváez, M., Ambrogini, P., Ferraro, L., Brito, I., Romero-Fernandez, W., Andrade-Talavera, Y., Flores-Burgess, A., Millon, C., Gago, B., et al. (2018) · Molecules · doi:10.3390/molecules23061341 · Cited by 50
“The participation of TM4 and TM5 in the oligomer interface has also been demonstrated within other complexes such as the serotonin 5-HT4 receptor homodimer [72], the chemokine CCR5 receptor homodimer [78], the α-factor pheromone receptor (Ste2) homodimer [79], the corticotrophin-releasing hormone receptor/arginine vas…”
BackgroundGiorgi, O., Corda, M. G., & Fernández‐Teruel, A. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00145 · Cited by 55
Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder
Cumming, P. D., Abi‐Dargham, A., & Gründer, G. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113004 · Cited by 60
“For example, the mGluR2 subtype forms a functional complex with cortical 5HT2A receptors, and their activation interferes in the physiological and behavior effects of psychedelic drugs [135].”
BackgroundRunge, K., Mathieu, R., Bugeon, S., Lafi, S., Beurrier, C., Sahu, S., Schaller, F., Loubat, A., Hérault, L., Gaillard, S., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01179-x · Cited by 57
Liu, W., Downing, A. C., Munsie, L. M., Chen, P., Reed, M. R., Ruble, C., Landschulz, K. T., Kinon, B. J., & Nisenbaum, L. K. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.90 · Cited by 57
Mondal, S., Khelashvili, G., & Weinstein, H. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.04.032 · Cited by 56
“…have remained unclear and are currently under intense scrutiny, including the molecular mechanisms driving the spatial organization of GPCRs on the cell surface and the relation of oligomerization to function (16,17,59–61, 64, The central principles of these explanations are the following: 1.”
BackgroundHeterodimers and Receptor Mosaics of Different Types of G-Protein-Coupled Receptors
Fuxe, K., Marcellino, D., Guidolin, D., Woods, A. S., & Agnati, L. F. (2008) · Physiology · doi:10.1152/physiol.00028.2008 · Cited by 52
Albizu, L., Moreno, J. L., González‐Maeso, J., & Sealfon, S. C. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793361586 · Cited by 61
Self-citationBelmer, A., Klenowski, P. M., Patkar, O. L., & Bartlett, S. E. (2016) · Brain Structure and Function · doi:10.1007/s00429-016-1278-x · Cited by 60
Huang, K.-C., Yang, K.-C., Lin, H., Tsao, T. T.-H., & Lee, S.-A. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s9-s6 · Cited by 51
“The complexes searched against CORUM revealed that the 2AR-mGluR2 complex involved in altered cortical process might be potential target for treatment of schizophrenia due to interaction with HTR2A (2AR) and metabotropic glutamate receptors (mGluR)[81].”
BackgroundPałucha-Poniewiera, A., Brański, P., Lenda, T., & Pilc, A. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169730 · Cited by 55
“…have shown the structural and functional interaction between the serotonergic and glutamatergic systems and its implication in psychiatric diseases such as psychosis and anxiety (Marek et al., 2000; Klodzinska et al., 2002; Stachowicz et al., 2007a, 2007b, 2009; González-Maeso et al., 2008).”
BackgroundGorinski, N., Kowalsman, N., Renner, U., Wirth, A., Reinartz, M. T., Seifert, R., Zeug, A., Ponimaskin, E. G., & Niv, M. Y. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079137 · Cited by 51
“The clinical significance of GPCR oligomerization has also become more evident during recent years, leading to identification of receptor oligomers as novel therapeutic targets (Waldhoer et al., 2005; Gonza´lez-Maeso et al., 2008).”
BackgroundInfluentialRiga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.049 · Cited by 53
Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action
Canal, C. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_107 · Cited by 53
“Also, 5-HT2A and glutamate mGluR2 receptors interact closely, and their interaction may be a key mechanism underlying psychedelic effects (Benneyworth et al. 2007; Delille et al. 2012; Gonzalez-Maeso et al. 2008; Lee et al. 2014; Moreno et al. 2011).”
BackgroundSerotonin and Glutamate Interactions in Preclinical Schizophrenia Models
Shah, U. H., & González‐Maeso, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00044 · Cited by 55
Self-citationUnderstanding the neurobiological effects of drug abuse: Lessons from zebrafish models
Müller, T. E., Fontana, B. D., Bertoncello, K. T., Franscescon, F., Mezzomo, N. J., Canzian, J., Stefanello, F. V., Parker, M. O., Gerlai, R. T., & Rosemberg, D. B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109873 · Cited by 57
Recent advances in postmortem pathology and neurochemistry in schizophrenia
Dean, B., Boer, S., Gibbons, A., Money, T., & Scarr, E. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328323d52e · Cited by 51
Cheah, S.-Y., Lawford, B., Young, R., Morris, C., & Voisey, J. (2017) · Genes · doi:10.3390/genes8010014 · Cited by 50
“However, one cohort of antipsychotic-free patients revealed upregulation of HTR2A receptor density in the prefrontal regions [14,15].”
BackgroundJalal, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5042-1 · Cited by 56
Malikowska‐Racia, N., & Sałat, K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.001 · Cited by 52
Bodzęta, A., Scheefhals, N., & MacGillavry, H. D. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108799 · Cited by 53
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 58
“The 5 ‐ HT2A receptor mediated hallucinogen ‐ specific intracellular pathway may require a complex of the 5 ‐ HT2A receptor with the mGlu2 receptor (Frecska, Bokor et al., 2016; Gonzalez ‐ Maeso et al., 2008; Moreno et al., 2011).”
Pozzi, L., Baviera, M., Sacchetti, G., Calcagno, E., Balducci, C., Invernizzi, R. W., & Carli, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.060 · Cited by 49
Hounsou, C., Margathe, J., Oueslati, N., Belhocine, A., Dupuis, E., Thomas, C., Mann, A., Ilien, B., Rognan, D., Trinquet, E., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb5007568 · Cited by 49
mGlu3 receptor and astrocytes: Partners in neuroprotection
Durand, D., Carniglia, L., Caruso, C. M., & Lasaga, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.009 · Cited by 52
Revenga, M. D. L. F., Ibi, D., Cuddy, T., Toneatti, R., Kurita, M., Ijaz, M. K., Miles, M. F., Wolstenholme, J. T., & González‐Maeso, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0143-4 · Cited by 54
Self-citationGrigoriadis, D. E., Hoare, S. R. J., Lechner, S. M., Slee, D. H., & Williams, J. A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.149 · Cited by 52
“…of heterodimer formation between the serotonin 5-HT2A (class A) receptor and the mGluR2 (class C) receptor and this dimer is involved in psychosis (Gonza- lez-Maeso et al, 2008) is evidence that ‘drugability’ of targets need not be restricted to single molecular entities with a nice well-defined…”
BackgroundPsilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia
Brogaard, B. “., & Gatzia, D. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00083-2 · Cited by 50
Jaster, A. M., Elder, H., Marsh, S. A., Revenga, M. D. L. F., Negus, S. S., & González‐Maeso, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06092-x · Cited by 51
Self-citationPharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
Gaitonde, S. A., Avet, C., Revenga, M. D. L. F., Blondel-Tepaz, É., Shahraki, A., Pastor, A. M., Talagayev, V., Robledo, P., Kolb, P., Selent, J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02531-7 · Cited by 50
Self-citationClinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia
Kinon, B. J., & Gómez, J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.002 · Cited by 48
“These results are provocative in view of preclinical data demonstrating that the excitatory effects of serotonin on pyramidal neurons may be blocked by mGluR2/3 agonists (Marek et al., 2000; González-Maeso et al., 2008).”
ResultFunctional Signaling Biases in G Protein-Coupled Receptors: Game Theory and Receptor Dynamics
Maudsley, S. R., Patel, S., Park, S.-S., Luttrell, L. M., & Martin, B. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712800959071 · Cited by 48
Wierońska, J. M., Zorn, S. H., Doller, D., & Pilc, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.007 · Cited by 55
Oligomerization of a G protein-coupled receptor in neurons controlled by its structural dynamics
Møller, T. C., Hottin, J., Clerté, C., Zwier, J. M., Durroux, T., Rondard, P., Prézeau, L., Royer, C. A., Pin, J., Margeat, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28682-6 · Cited by 50
Dimers of serotonin receptors: Impact on ligand affinity and signaling
Maroteaux, L., Béchade, C., & Roumier, A. (2019) · Biochimie · doi:10.1016/j.biochi.2019.01.009 · Cited by 48
Abnormal synaptic plasticity and impaired cognition in schizophrenia
Wu, X., Yan, Q., & Zhu, F. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i4.541 · Cited by 48
Moreno, J. L., Holloway, T., Rayannavar, V., Sealfon, S. C., & González-Maeso, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.12.053 · Cited by 44
Self-citationMolecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation
Gregory, K. J., & Conn, P. J. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097220 · Cited by 48
Endogenous Serotonin 5-HT2A and 5-HT2C Receptors Associate in the Medial Prefrontal Cortex
Price, A. E., Sholler, D. J., Stutz, S. J., Anastasio, N. C., & Cunningham, K. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00669 · Cited by 46
Differential effects of 5-HT2A and 5-HT2C receptor blockade on strategy-switching
Baker, P. M., Thompson, J. L., Sweeney, J. A., & Ragozzino, M. E. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.12.031 · Cited by 46
“In the treatment of symptoms in schizophrenia, several atypical anti-psychotics antagonize 5-HT2 receptors and in some cases are effective in reducing cognitive symptoms [22, 30, 52].”
BackgroundG protein‐coupled receptors: walking hand‐in‐hand, talking hand‐in‐hand?
Vischer, H. F., Watts, A. O., Nijmeijer, S., & Leurs, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01229.x · Cited by 56
“Interestingly, opposite binding cooperativity was observed within 5-HT2A/mGlu2 receptor heteromers in mouse somatosensory cortex membranes (Gonzalez-Maeso et al., 2008).”
Liester, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120522 · Cited by 45
“For example, activation of mGlu2 receptors inhibits hallucinogen-specific neuronal signaling pathways induced by hallucinogenic 5-HT2A receptor agonists [18].”
BackgroundNicoletti, F., Orlando, R., Menna, L. D., Cannella, M., Notartomaso, S., Mascio, G., Iacovelli, L., Matrisciano, F., Fazio, F., Caraci, F., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00049 · Cited by 48
Metadata
- Authors
- González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., & Sealfon, S. C.
- Affiliations
- University of the Basque Country (ES)
- University of Glasgow (GB)
- New York State Psychiatric Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Sealfon, Stuart C.
- ORCID
- Venue
- Nature
- Published
- 2008-02-24
- Volume
- 452
- Issue
- 7183
- Pages
- 93-97
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2743172
- OpenAlex
- W2024942419
- Cited by
- 803
- References
- 44
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 23 · 2023: 34 · 2022: 44 · 2021: 38 · 2020: 36 · 2019: 33 · 2018: 45 · 2017: 44 · 2016: 51 · 2015: 37 · 2014: 52 · 2013: 62 · 2012: 71
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH083545)
- National Institute on Drug Abuse (T32DA007135, P01DA012923)
- National Institute of General Medical Sciences (T32GM062754)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 5-HT2A receptor, mGluR2, metabotropic glutamate receptors, receptor complex, schizophrenia, psychosis, hallucinogens, LSD, psilocybin, cortical dysfunction, antipsychotic drug targets, postmortem brain
- MeSH terms
- Animals, Brain, Cell Line, Cells, Cultured, Hallucinogens, Humans, Models, Molecular, Protein Binding, Psychotic Disorders, Schizophrenia, Signal Transduction, Down-Regulation, Up-Regulation, Protein Structure, Tertiary, Receptors, Metabotropic Glutamate, Receptor, Serotonin, 5-HT2A, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.